Identifying Barriers To Implementing Guidelines For Monitoring Metabolic Syndrome In Patients Prescribed Second-Generation Antipsychotics In Incarcerated Populations

<p>Individuals with serious mental illness (SMI) have increased rates of cardiovascular disease (CVD) and mortality. Also, the evidence indicates that second-generation antipsychotics (SGAs, a conventional treatment) increase the risk of metabolic syndrome (MetS) often leading to weight gain, cardiovascular disease (CVD) and type 2 diabetes (DM 2). U. S. correctional institutions, faced with increased rates of mental illness in its population, are confronted with the need to assure adequate monitoring for its patients treated with SGAs. This paper reviews guidelines for monitoring incarcerated patients to ensure early intervention that can improve clinical outcomes. Characteristics of the incarcerated population and institution-related barriers to implementing guidelines are identified along with strategies for improved monitoring and issues for further study.</p>

Name thesis:degree_name

Doctor of Nursing Practice (DNP)

Level thesis:degree_level

Open Access Thesis

Discipline thesis:degree_discipline

Yale University School of Nursing

Year

2017

Author dc:creator

• Cenac, Carol-Ann Margaret

Contributors dc:contributor

• Joanne Iennaco

• barriers to care
• mental illness in U. S. jails and prisons
• metabolic syndrome
• Second generation antipsychotics

Repository record dc:identifier

https://elischolar.library.yale.edu/ysndt/1054

OAI identifier oai:identifier

oai:elischolar.library.yale.edu:ysndt-1053